DDInter202 DDInter1562
Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.
Raloxifene is a second generation selective estrogen receptor modulator (SERM) that mediates anti-estrogenic effects on breast and uterine tissues, and estrogenic effects on bone, lipid metabolism, and blood coagulation.[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal women and reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis or those who are at high risk for invasive breast cancer. However, it has a negligible effect on altering the development and progression of breast cancer itself.[label] The most common causes of osteoporosis include postmenopausal deficiency of estrogen and age-related deterioration in bone homeostasis. Due to the risk of bone fractures that may lead to morbidities and reduced quality of life, the management of osteoporosis in postmenopausal women with the use of therapeutic agents in addition to concurrent therapies is critical. Due to the decline in estrogen levels in postmenopausal osteoporosis, hormone replacement therapy (HRT), such as estradiol, has been used to ameliorate the condition. However, due to the off-target actions by HRT, newer non-hormonal agents such as raloxifene and [tamoxifen] have been developed to reduce adverse events through selective pharmacological actions on tissue-specific therapeutic targets. The main effects of raloxifene are to preserve the bone mineral density and decrease the risk of breast cancer in postmenopausal women. Compared to estrogen and tamoxifen, raloxifene was not associated with an increased risk of uterine cancer and it does not cause endometrial proliferation. Although rare, there was an increased risk of venous thromboembolism during clinical trials of postmenopausal women receiving raloxifene. In addition, a clinical study consisting of postmenopausal women with documented coronary heart disease or at increased risk for coronary events showed an increased risk for fatal stroke with raloxifene therapy compared to placebo.[label] It is strongly advised that the risk-benefit ratio is considered before starting raloxifene therapy in women at risk of thromboembolic disease or strokes, such as the prior history of stroke, transient ischemic attack, atrial fibrillation, hypertension, or cigarette smoking.[label]
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) causes {v} (Side Effect) Cramps of lower extremities
Cramps of lower extremities {u} (Side Effect) is caused by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Flavoxate
Flavoxate {u} (Compound) resembles {v} (Compound) Raloxifene
Bexarotene {u} (Compound) resembles {v} (Compound) Tamibarotene
Tamibarotene {u} (Compound) upregulates {v} (Gene) KLHDC2
KLHDC2 {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) HSD17B4
HSD17B4 {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) downregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is upregulated by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) resembles {v} (Compound) Tamibarotene
Tamibarotene {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) interacts with {v} (Gene) STUB1
STUB1 {u} (Gene) is downregulated by {v} (Compound) Raloxifene
Bexarotene {u} (Compound) binds {v} (Gene) RXRG
RXRG {u} (Gene) interacts with {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Raloxifene
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Raloxifene (Compound)
Bexarotene (Compound) causes Cramps of lower extremities (Side Effect) and Cramps of lower extremities (Side Effect) is caused by Raloxifene (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with breast cancer (Disease) and breast cancer (Disease) is treated by Raloxifene (Compound)
Bexarotene (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Flavoxate (Compound) and Flavoxate (Compound) resembles Raloxifene (Compound)
Bexarotene (Compound) resembles Tamibarotene (Compound) and Tamibarotene (Compound) upregulates KLHDC2 (Gene) and KLHDC2 (Gene) is upregulated by Raloxifene (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with HSD17B4 (Gene) and HSD17B4 (Gene) is upregulated by Raloxifene (Compound)
Bexarotene (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) downregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is upregulated by Raloxifene (Compound)
Bexarotene (Compound) resembles Tamibarotene (Compound) and Tamibarotene (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Raloxifene (Compound)
Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) interacts with STUB1 (Gene) and STUB1 (Gene) is downregulated by Raloxifene (Compound)
Bexarotene (Compound) binds RXRG (Gene) and RXRG (Gene) interacts with DCK (Gene) and DCK (Gene) is downregulated by Raloxifene (Compound)